Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493514 | 1.00 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL30300609 | 1.00 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL163120 | 1.00 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| Ammonia Solution, Strong SCHEMBL28013340 | 0.98 | CA2 (0.50) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL28313964 | 0.98 | CA2 (0.50) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL27569182 | 0.98 | CA2 (0.50) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL28472977 | 0.98 | CA2 (0.50) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL28479156 | 0.98 | CA2 (0.50) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL1650575 | 0.98 | CA2 (0.50) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL28476908 | 0.98 | CA2 (0.50) | CA2CA4CA1MMETGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679086-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| CN-113195003-B | Drug delivery system using solution | 国立大学法人京都大学 | 2024-12-31 | — | — | CN | claimed |
| WO-2024257872-A1 | METHOD FOR PREDICTING GENE TRANSFER RATE | 武田薬品工業株式会社 | 2024-12-19 | — | — | WO | claimed |
| WO-2024190663-A1 | BIOMARKER AND USE THEREOF | 株式会社明治 | 2024-09-19 | — | — | WO | claimed |
| US-20240255510-A1 | SALIVARY METABOLITES ARE NON-INVASIVE BIOMARKERS OF HCC | THE CLEVELAND CLINIC FOUNDATION | 2024-08-01 | — | — | US | claimed |
| EP-4337784-A1 | SALIVARY METABOLITES ARE NON-INVASIVE BIOMARKERS OF HCC | The Cleveland Clinic Foundation (US) | 2024-03-20 | — | — | EP | claimed |
| CN-117388421-A | Method for identifying forage grass rhizosphere secretion and differential metabolite thereof based on non-targeted metabonomics | 中国农业大学 | 2024-01-12 | — | — | CN | claimed |
| CN-112779303-B | Method for synthesizing orotic acid by biological enzyme method | 华东理工大学 | 2023-05-02 | — | — | CN | claimed |
| CN-105765383-A | SALIVARY BIOMARKER FOR CANCER, METHOD AND DEVICE FOR ASSAYING SAME, AND METHOD FOR DETERMINING SALIVARY BIOMARKER FOR CANCER | 唾液科技有限公司 | 2016-07-13 | — | — | CN | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| US-8956833-B2 | Methods for control of flux in metabolic pathways through enzyme relocation | GREENLIGHT BIOSCIENCES, INC. (US) | 2015-02-17 | — | — | US | claimed |
| CN-103826633-A | Methylphenidate prodrugs, methods of making and using the same | KEMPHARM INC | 2014-05-28 | — | — | CN | claimed |
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-08-02 | — | — | US | claimed |
| WO-2010141883-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-09 | — | — | WO | claimed |
| EP-1465616-B1 | TREATMENT OF STATIN SIDE EFFECTS USING URIDINE DERIVATIVES | MAGRAL LTD (AU) | 2010-06-30 | — | — | EP | claimed |
| EP-1343488-B1 | TREATMENT OF STATIN SIDE EFFECTS | MAGRAL LTD (AU) | 2007-08-15 | — | — | EP | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0173276-A2 | Method for the determination of substrate or enzyme activity | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1986-03-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | HLA-DRB1, MICA, CD74 | CA2 714/4885CA4 559/4885CA1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.